New Diabetes Drug May Work Better than Byetta: Roche announced last week that its GLP-1 drug, taspoglutide (which is still in phase 3 trials), worked better than Byetta in lowering blood sugar, according to the results of a late stage study. The study marks a small step on the way to possible approval of the drug, for which Roche has seven additional trials underway. After 24 weeks of treatment, patients who had been given taspoglutide experienced a bigger decline in their blood sugar than those who had been given Byetta. Results to be published shortly in a major diabetes journal.